Legal Opinion
Amgen, Inc. v. Genetics Institute, Inc.
District Court, D. Massachusetts
Decided February 14, 1995No. Civ. A. 94-11818-WGYPublishedCited by 1 opinion
1Opinion of the Court
MEMORANDUM AND ORDER
YOUNG, District Judge.
This action is the latest front in a scientific and legal war, now into its second decade, over the production and purification of erythropoietin (“EPO”). 1 EPO is a human protein that stimulates the production of red blood cells and is used primarily for the clinical treatment of anemia, particularly anemia caused by renal disease. 2 The parties to this action are two biotechnology firms, Amgen, Inc. (“Amgen”) and Genetics, Inc. (“Genetics”), which have obtained certain patents over the years relating to EPO. A prior patent infringement action…
2Cases cited23 opinions
- Celotex Corp. v. Catrett, Administratrix of the Estate of CatrettSupreme Court of the United States · 1986
- Bonito Boats, Inc. v. Thunder Craft Boats, Inc.Supreme Court of the United States · 1989
- Casas Office MacHines, Inc. v. Mita Copystar America, Inc.Court of Appeals for the First Circuit · 1995
- O'Reilly v. MorseSupreme Court of the United States · 1854
- Charles C. Johnston and Gordon P. Ramsey, as Trustees of the Amec Liquidating Trust v. Ivac CorporationCourt of Appeals for the Federal Circuit · 1989
18 more not listed; retrieve them via the Exa API.
3Cited by1 opinion
- Amgen, Inc. v. Hoechst Marion Roussel, Inc.District Court, D. Massachusetts · 2001